Cargando…
CRISPR screening identifies T cell-intrinsic regulators of CD3-bispecific antibody responses
CD3-engaging bispecific antibodies (BsAbs) enable the formation of an immune synapse between T cells and tumor cells, resulting in robust target cell killing not dependent on a preexisting tumor specific T cell receptor. While recent studies have shed light on tumor cell-specific factors that modula...
Autores principales: | Molony, Ryan D., Funk, Theresa, Trabucco, Gina, Corcoran, Erik, Ruddy, David, Varadarajan, Malini, Elliot, GiNell, Piquet, Michelle, Lam, Joni, Meyer, Matthew J., Wang, Hui Qin, Kurtulus, Sema, Lu, Haihui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388929/ https://www.ncbi.nlm.nih.gov/pubmed/35990699 http://dx.doi.org/10.3389/fimmu.2022.909979 |
Ejemplares similares
-
Genome-scale CRISPR activation screen uncovers tumor-intrinsic modulators of CD3 bispecific antibody efficacy
por: Decker, Corinne E., et al.
Publicado: (2019) -
γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation
por: Chen, Hailin, et al.
Publicado: (2022) -
Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII‐equivalence
por: Leksa, Nina C., et al.
Publicado: (2019) -
Bispecific antibodies and their applications
por: Fan, Gaowei, et al.
Publicado: (2015) -
The making of bispecific antibodies
por: Brinkmann, Ulrich, et al.
Publicado: (2017)